Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mecasermin
- Development stage
- Approved
- Lead developer
- Ipsen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intratendinous, Subcutaneous
01
Overview
Mecasermin is a recombinant human insulin-like growth factor-1 (rhIGF-1) that mimics the effects of endogenous IGF-1, a key mediator of growth hormone-induced somatic growth and a potent stimulator of collagen synthesis. In a clinical investigation led by Bispebjerg Hospital, mecasermin was evaluated for its ability to stimulate collagen production in the patellar tendon, muscle, and skin of patients with classic Ehlers-Danlos syndrome (EDS). Classic EDS is a connective tissue disorder typically caused by defects in type V collagen, resulting in joint hypermobility and skin fragility. The study (NCT01446783) utilized local intratendinous injections to determine if IGF-1 receptor activation could improve the structural integrity of compliant connective tissues in these patients.
- Brand names
- Increlex
- Other names
- recombinant human insulin-like growth factor-IrhIGF-IIGF-I
02
Targets
INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)IGF2R (Cation-independent mannose-6-phosphate receptor)α6β4 (Integrin alpha-6 beta-4)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on mecasermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mecasermin.